CD4 and neoplasm: Immune profiling of the tumors after treatment reveals the induction of robust dendritic cells (DCs), and CD4+ T cell increase to present tumor antigen and recruitment of tumor‐infiltrating CD8+ T cells to kill tumor cells, while with a significant upregulation of Ki67 in CD8+ T cells, indicating enhanced proliferation.